GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Enterprise Value

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Enterprise Value : ¥9,229.24 Mil (As of Jun. 25, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chongqing Genrix Biopharmaceutical Co's Enterprise Value is ¥9,229.24 Mil. Chongqing Genrix Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-730.96 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's EV-to-EBIT ratio for today is -12.63.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Chongqing Genrix Biopharmaceutical Co's Enterprise Value is ¥9,229.24 Mil. Chongqing Genrix Biopharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-728.97 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's EV-to-EBITDA ratio for today is -12.66.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Chongqing Genrix Biopharmaceutical Co's Enterprise Value is ¥9,229.24 Mil. Chongqing Genrix Biopharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1.12 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue ratio for today is 8,262.52.


Chongqing Genrix Biopharmaceutical Co Enterprise Value Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Enterprise Value Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - - - 12,370.01

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8,796.17 8,905.85 12,370.01 12,650.36

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Enterprise Value

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Enterprise Value falls into.



Chongqing Genrix Biopharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Chongqing Genrix Biopharmaceutical Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Chongqing Genrix Biopharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Chongqing Genrix Biopharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=9229.240/-730.959
=-12.63

Chongqing Genrix Biopharmaceutical Co's current Enterprise Value is ¥9,229.24 Mil.
Chongqing Genrix Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-730.96 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Chongqing Genrix Biopharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=9229.240/-728.969
=-12.66

Chongqing Genrix Biopharmaceutical Co's current Enterprise Value is ¥9,229.24 Mil.
Chongqing Genrix Biopharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-728.97 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9229.240/1.117
=8,262.52

Chongqing Genrix Biopharmaceutical Co's current Enterprise Value is ¥9,229.24 Mil.
Chongqing Genrix Biopharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines